Loading...

KP Tissue

OTCPK:KPTS.F
Snowflake Description

Mediocre balance sheet unattractive dividend payer.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
KPTS.F
OTCPK
CA$77M
Market Cap
  1. Home
  2. US
  3. Household
Company description

KP Tissue Inc., through its interest in Kruger Products L.P., produces, distributes, markets, and sells a range of disposable tissue products in North America. The last earnings update was 47 days ago. More info.


Add to Portfolio Compare Print
KPTS.F Share Price and Events
7 Day Returns
0%
OTCPK:KPTS.F
0.8%
US Household Products
1.4%
US Market
1 Year Returns
-
OTCPK:KPTS.F
38.5%
US Household Products
4.9%
US Market
KPTS.F Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
KP Tissue (KPTS.F) 0% -0.1% -10.8% - - -
US Household Products 0.8% 4.5% 7.8% 38.5% 35.1% 46.5%
US Market 1.4% 3.8% 3.5% 4.9% 44.8% 40.1%
1 Year Return vs Industry and Market
  • No trading data on KPTS.F.
  • No trading data on KPTS.F.
Price Volatility
KPTS.F
Industry
5yr Volatility vs Market
Related Companies

KPTS.F Value

 Is KP Tissue undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for KP Tissue. This is due to cash flow or dividend data being unavailable. The share price is $6.03001.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for KP Tissue's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are KP Tissue's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:KPTS.F PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in CAD CA$-0.14
TSX:KPT Share Price ** TSX (2019-06-04) in CAD CA$8.11
United States of America Household Products Industry PE Ratio Median Figure of 9 Publicly-Listed Household Products Companies 25.03x
United States of America Market PE Ratio Median Figure of 3,095 Publicly-Listed Companies 17.73x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of KP Tissue.

OTCPK:KPTS.F PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSX:KPT Share Price ÷ EPS (both in CAD)

= 8.11 ÷ -0.14

-59.07x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • KP Tissue is loss making, we can't compare its value to the US Household Products industry average.
  • KP Tissue is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does KP Tissue's expected growth come at a high price?
Raw Data
OTCPK:KPTS.F PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -59.07x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
Not available
United States of America Household Products Industry PEG Ratio Median Figure of 7 Publicly-Listed Household Products Companies 4.23x
United States of America Market PEG Ratio Median Figure of 2,133 Publicly-Listed Companies 1.53x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for KP Tissue, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on KP Tissue's assets?
Raw Data
OTCPK:KPTS.F PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in CAD CA$9.70
TSX:KPT Share Price * TSX (2019-06-04) in CAD CA$8.11
United States of America Household Products Industry PB Ratio Median Figure of 12 Publicly-Listed Household Products Companies 2.91x
United States of America Market PB Ratio Median Figure of 5,255 Publicly-Listed Companies 1.79x
OTCPK:KPTS.F PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSX:KPT Share Price ÷ Book Value per Share (both in CAD)

= 8.11 ÷ 9.70

0.84x

* Primary Listing of KP Tissue.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • KP Tissue is good value based on assets compared to the US Household Products industry average.
X
Value checks
We assess KP Tissue's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Household Products industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Household Products industry average (and greater than 0)? (1 check)
  5. KP Tissue has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

KPTS.F Future Performance

 How is KP Tissue expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as KP Tissue has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
7.2%
Expected Household Products industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is KP Tissue expected to grow at an attractive rate?
  • Unable to compare KP Tissue's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare KP Tissue's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare KP Tissue's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:KPTS.F Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Household Products Industry Earnings Growth Rate Market Cap Weighted Average 7.2%
United States of America Household Products Industry Revenue Growth Rate Market Cap Weighted Average 3.3%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:KPTS.F Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:KPTS.F Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 1,493 74 2
2019-12-31 1,448 50 2
OTCPK:KPTS.F Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-03-31 0 -1
2018-12-31 0 0
2018-09-30 0 -7
2018-07-01 0 -6
2018-04-01 0 -6
2017-12-31 0 -5
2017-09-24 0 -2
2017-06-25 0 -1
2017-03-26 0 -1
2016-12-31 0 -2
2016-09-25 0 -29
2016-06-26 0 -32

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if KP Tissue is high growth as no earnings estimate data is available.
  • Unable to determine if KP Tissue is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:KPTS.F Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from KP Tissue Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:KPTS.F Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31
2019-12-31
OTCPK:KPTS.F Past Financials Data
Date (Data in CAD Millions) EPS *
2019-03-31 -0.14
2018-12-31 -0.02
2018-09-30 -0.78
2018-07-01 -0.70
2018-04-01 -0.62
2017-12-31 -0.59
2017-09-24 -0.18
2017-06-25 -0.09
2017-03-26 -0.09
2016-12-31 -0.19
2016-09-25 -3.23
2016-06-26 -3.55

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if KP Tissue will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of KPTS.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. KP Tissue's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Household companies here
  3. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access KP Tissue's filings and announcements here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess KP Tissue's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
KP Tissue has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

KPTS.F Past Performance

  How has KP Tissue performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare KP Tissue's growth in the last year to its industry (Household Products).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • KP Tissue does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare KP Tissue's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare KP Tissue's 1-year growth to the US Household Products industry average as it is not currently profitable.
Earnings and Revenue History
KP Tissue's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from KP Tissue Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:KPTS.F Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 -1.29
2018-12-31 -0.17
2018-09-30 -7.22
2018-07-01 -6.46
2018-04-01 -5.72
2017-12-31 -5.44
2017-09-24 -1.63
2017-06-25 -0.79
2017-03-26 -0.81
2016-12-31 -1.72
2016-09-25 -29.09
2016-06-26 -31.84
2016-03-27 -32.19
2015-12-31 -31.34
2015-09-27 -4.82
2015-06-28 -2.15
2015-03-29 -1.47
2014-12-31 -2.52
2014-09-28 -1.98
2014-06-29 -2.15
2014-03-30 -1.28
2013-12-31 -0.29
2013-09-29 -7.55
2012-12-31 -3.36
2012-09-23 5.27

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if KP Tissue has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if KP Tissue has efficiently used its assets last year compared to the US Household Products industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if KP Tissue improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess KP Tissue's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Household Products industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
KP Tissue has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

KPTS.F Health

 How is KP Tissue's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up KP Tissue's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • KP Tissue is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • KP Tissue's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of KP Tissue's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • KP Tissue has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from KP Tissue Company Filings, last reported 2 months ago.

OTCPK:KPTS.F Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 91.89 0.00
2018-12-31 98.77 0.00
2018-09-30 96.06 0.00
2018-07-01 96.71 0.00
2018-04-01 98.08 0.00
2017-12-31 96.93 0.00
2017-09-24 102.64 0.00
2017-06-25 108.49 0.00
2017-03-26 112.72 0.00
2016-12-31 115.08 0.00
2016-09-25 107.14 0.00
2016-06-26 109.96 0.00
2016-03-27 117.61 0.00
2015-12-31 125.22 0.00
2015-09-27 150.35 0.00
2015-06-28 148.43 0.00
2015-03-29 149.07 0.00
2014-12-31 150.60 0.00
2014-09-28 150.31 0.00
2014-06-29 148.91 0.00
2014-03-30 157.04 0.00
2013-12-31 157.97 0.00
2013-09-29 156.13 0.00
2012-12-31 139.60 0.00
2012-09-23 140.00 0.00
  • KP Tissue has no debt.
  • KP Tissue has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Information is not available.
  • Unable to confirm if KP Tissue has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess KP Tissue's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. KP Tissue has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

KPTS.F Dividends

 What is KP Tissue's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
8.88%
Current annual income from KP Tissue dividends. Estimated to be 8.88% next year.
If you bought $2,000 of KP Tissue shares you are expected to receive $178 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • KP Tissue's pays a higher dividend yield than the bottom 25% of dividend payers in United States of America (1.45%).
  • KP Tissue's dividend is above the markets top 25% of dividend payers in United States of America (3.73%).
Upcoming dividend payment

Purchase KP Tissue before the 'Buy Limit' to receive their next dividend payment.

Dividends are usually paid every 3 or 6 months, you can time your share purchase to take advantage of upcoming dividend payments.
Dividend payment calendar
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:KPTS.F Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
United States of America Household Products Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 2.6%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2012 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OTCPK:KPTS.F Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts
2020-12-31 0.72 2.00
2019-12-31 0.72 2.00
OTCPK:KPTS.F Past Annualized Dividends Data
Date (Data in CA$) Dividend per share (annual) Avg. Yield (%)
2019-05-10 0.720 8.923
2019-03-07 0.720 8.370
2018-08-09 0.720 8.265
2018-03-08 0.720 6.795
2017-11-08 0.720 5.317
2017-08-09 0.720 4.841
2017-05-04 0.720 4.906
2017-03-09 0.720 4.609
2016-11-03 0.720 4.718
2016-08-10 0.720 5.172
2016-05-05 0.720 5.711
2016-03-10 0.720 5.568
2015-08-12 0.720 5.884
2015-05-07 0.720 4.759
2015-03-12 0.720 4.461
2014-11-12 0.720 4.211
2014-08-13 0.720 4.509
2014-05-09 0.720 4.522
2014-03-19 0.720 4.501
2013-11-13 0.720 4.220
2013-08-13 0.720 4.172
2013-05-14 0.720 4.191
2013-03-27 0.720 3.811

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, KP Tissue has been paying a dividend for less than 10 years.
  • KP Tissue has only been paying a dividend for 6 years, and since then there has been no growth.
Current Payout to shareholders
What portion of KP Tissue's earnings are paid to the shareholders as a dividend.
  • The company is paying a dividend however it is incurring a loss.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess KP Tissue's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can KP Tissue afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. KP Tissue has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

KPTS.F Management

 What is the CEO of KP Tissue's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Dino Bianco
COMPENSATION CA$1,436,469
AGE 56
TENURE AS CEO 1.3 years
CEO Bio

Mr. Dino J. Bianco has been a Director of Welbilt, Inc. (formerly known as Manitowoc Foodservice, Inc.) since May 2015. He served as an Executive Vice President at Kraft Foods Group, Inc., from 2012 to April 2015 and served as its President of Beverages from 2013 to April 2015. Mr. Bianco has served as Chief Executive Officer of KP Tissue Inc. and Kruger Products L.P. since March 9, 2018 and also serves as a Director of KPGP, Inc., the general Partner of Kruger Products L.P. Mr. Bianco served as President of Beverages and Canada at Kraft Foods Group, Inc., since January 2013. Mr. Bianco served as President of National Businesses & Marketing Services at Kraft Foods Group, Inc. since October 1, 2012. He leads Kraft’s Foodservice, Canada, Marketing Services and Export organizations. He served as the President at Kraft Canada, Inc. since November 2005. Prior to that, he served as Senior Vice President and General Manager of Kraft Canada Inc since November 2005. He is a director of MTW from 2015. He has more than 15 years of experience with Kraft and has held senior positions in Finance, Sales and Marketing, including Vice President, Beverages and Cereal, Kraft Canada. He served as Vice President of Mondelez International, Inc. (alternate name Kraft Foods Inc.). He began his career at Kraft as a finance manager in 1990 after spending three years at PriceWaterhouseCoopers. His extensive multifunctional background positions him well to lead the Canadian business, including overseeing local marketing and programming, building sales partnerships, managing government and public affairs issues and guiding talent management in Canada. He served as Director of Andrew Peller Limited from October 1, 2016 to January 15, 2018. He served as an Independent Director of The Manitowoc Company, Inc. until March 4, 2016. He is a past chair and Board Member of the Food and Consumer Products of Canada and Global Standards 1 Canada. He was past chair of Food and Consumer Products of Canada, past member of the Board of The Grocery Foundation and past member of the Board of Trustees of the United Way of Toronto. Mr. Bianco is a chartered accountant and received his Bachelor of Commerce degree from the University of Toronto.

CEO Compensation
  • Insufficient data for Dino to compare compensation growth.
  • Dino's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure of the KP Tissue management team in years:

5.9
Average Tenure
  • The average tenure for the KP Tissue management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Dino Bianco

TITLE
Chief Executive Officer
COMPENSATION
CA$1M
AGE
56
TENURE
1.3 yrs

Mark Holbrook

TITLE
Chief Financial Officer
COMPENSATION
CA$664K

Michel Manseau

TITLE
Senior VP & GM of Consumer Business Canada - Kruger Products LP
COMPENSATION
CA$690K
TENURE
12.1 yrs

Gordon Goss

TITLE
Senior VP and GM of Consumer Business USA & Mexico - Kruger Products LP
COMPENSATION
CA$794K
TENURE
8.3 yrs

Marc Fitzgerald

TITLE
Corporate Vice President of Technology & Product Development - Kruger Products LP
TENURE
5.9 yrs

Mike Baldesarra

TITLE
Director of Investor Relations
TENURE
7.4 yrs

François Paroyan

TITLE
General Counsel & Corporate Secretary

Rob Latter

TITLE
Senior VP & GM of Away from Home Business - Kruger Products LP
COMPENSATION
CA$650K
TENURE
1.1 yrs

Nancy Marcus

TITLE
Chief Marketing Officer of Kruger Products L.P.
COMPENSATION
CA$606K
TENURE
1.1 yrs
Board of Directors Tenure

Average tenure of the KP Tissue board of directors in years:

3.4
Average Tenure
  • The tenure for the KP Tissue board of directors is about average.
Board of Directors

Michael Korenberg

TITLE
Chairman
COMPENSATION
CA$89K
AGE
57

Joseph Kruger

TITLE
Chairman of Kruger Products G.P.

Michel Letellier

TITLE
Independent Director
COMPENSATION
CA$75K
AGE
53
TENURE
6.7 yrs

Jim Hardy

TITLE
Independent Director
COMPENSATION
CA$89K
TENURE
5 yrs

Louise Denys Wendling

TITLE
Director
COMPENSATION
CA$39K
TENURE
1.1 yrs

David Angel

TITLE
Director of Kruger Products G.P

Gene Kruger

TITLE
Director of Kruger Products G.P.
TENURE
1.8 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by KP Tissue individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
23. May 19 Buy Michael Korenberg Individual 22. May 19 23. May 19 5,000 $6.04 $30,118
20. Dec 18 Buy Michel Letellier Individual 19. Dec 18 19. Dec 18 1,780 $5.85 $10,408
18. Dec 18 Sell Mario Gosselin Individual 18. Dec 18 18. Dec 18 -10,000 $5.99 $-59,509
29. Nov 18 Buy Michel Manseau Individual 27. Nov 18 27. Nov 18 1,000 $6.35 $6,353
27. Nov 18 Buy David Angel Individual 27. Nov 18 27. Nov 18 837 $6.28 $5,260
23. Nov 18 Buy David Angel Individual 22. Nov 18 23. Nov 18 1,060 $6.47 $6,757
22. Nov 18 Buy Gene Kruger Individual 22. Nov 18 22. Nov 18 11,800 $6.62 $76,577
29. Aug 18 Buy Joseph Kruger Individual 28. Aug 18 28. Aug 18 5,000 $7.66 $38,274
28. Aug 18 Buy David Angel Individual 27. Aug 18 27. Aug 18 600 $7.55 $4,529
21. Aug 18 Buy Joseph Kruger Individual 21. Aug 18 21. Aug 18 5,500 $7.73 $42,264
21. Aug 18 Buy Michael Korenberg Individual 20. Aug 18 20. Aug 18 5,000 $7.65 $37,893
X
Management checks
We assess KP Tissue's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. KP Tissue has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

KPTS.F News

Simply Wall St News

KPTS.F Company Info

Description

KP Tissue Inc., through its interest in Kruger Products L.P., produces, distributes, markets, and sells a range of disposable tissue products in North America. The company operates through three segments: Consumer Products, Away-From-Home, and Other. It offers bathroom and facial tissues, paper towels, and paper towels and napkins, as well as disposable wiping products and washroom dispensing systems. The company markets its products under the Cashmere, Purex, SpongeTowels, Scotties, White Swan, and White Cloud brand names. It sells its products to end-consumers through traditional retail channels, such as grocery stores, mass merchandisers, club and drug stores, and convenience stores; and commercial users in property management, healthcare, food services, manufacturing, education, and lodging industries, as well as in public facilities. KP Tissue Inc. was founded in 2012 and is headquartered in Mississauga, Canada.

Details
Name: KP Tissue Inc.
KPTS.F
Exchange: OTCPK
Founded: 2012
CA$58,662,068
9,523,436
Website: http://kptissueinc.com
Address: KP Tissue Inc.
1900 Minnesota Court,
Suite 200,
Mississauga,
Ontario, L5N 5R5,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSX KPT Common Shares The Toronto Stock Exchange CA CAD 13. Dec 2012
OTCPK KPTS.F Common Shares Pink Sheets LLC US USD 13. Dec 2012
DB KP8 Common Shares Deutsche Boerse AG DE EUR 13. Dec 2012
Number of employees
Current staff
Staff numbers
0
KP Tissue employees.
Industry
Household Products
Household
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/26 01:02
End of day share price update: 2019/06/04 00:00
Last estimates confirmation: 2019/05/29
Last earnings filing: 2019/05/10
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.